Jang S.Y.,Yonsei University |
Lee S.Y.,Yonsei University |
Lee E.J.,Severance Integrative Research Institute for Cerebral and Cardiovascular Disease |
Lee E.J.,Yonsei University |
Yoon J.S.,Yonsei University
Eye (Basingstoke) | Year: 2012
AimTo compare clinical characteristics and thyroid-stimulating hormone receptor antibodies (TRAbs) in thyroid-associated ophthalmopathy (TAO) in euthyroid Korean patients with those in hyperthyroid patients.MethodsClinical activity scores (CASs), modified NOSPECS scores, exophthalmometry values, prevalence of optic neuropathy, restrictive myopathy and lid retraction, and the positivity and levels of TRAb (thyrotropin-binding inhibitor immunoglobulin (TBII) and thyroid-stimulating immunoglobulin (TSI)) were compared in 24 euthyroid (group A) and 139 clinical/subclinical hyperthyroid TAO patients (group B).ResultsGroup A presented more clinically unilateral involvement than group B (79.2% vs 27.3%, P0.001), less active (CAS 1.50 vs 2.26, P0.014) and less severe clinical course (NOSPECS 3.38 vs 4.13, P0.037). Lid retraction was more prevalent in group A than group B (91.7% vs 66.2%, P0.014). Prevalence of optic neuropathy and restrictive myopathy, and the mean value of exophthalmometry were not different. Mean TBII levels were lower (7.20 IU/l) in group A than in group B (44.58 IU/l, P0.001). A similar difference was found in the TSI bioassay (201.40% vs 425.19%, P0.001). The positive rate of TBII in group A (34.8%) was significantly lower than in group B (90.8%, P0.001). The positive rate of TSI was high in both group A (83.3%) and B (91.7%), with no significant difference (P0.337).ConclusionsPatients with euthyroid TAO showed a less active and severe clinical course, more unilateral involvement, and lower levels of TRAb than those in patients with hyperthyroid TAO. These distinct clinical and biochemical characteristics might be useful in assessment of euthyroid TAO, and the TSI might be more sensitive for diagnosing these patients. © 2012 Macmillan Publishers Limited All rights reserved.
Hong Z.-Y.,Yonsei University |
Hong Z.-Y.,Severance Integrative Research Institute for Cerebral and Cardiovascular Disease |
Lee H.J.,Yonsei University |
Lee H.J.,Severance Integrative Research Institute for Cerebral and Cardiovascular Disease |
And 9 more authors.
Cancer Letters | Year: 2012
Akt-dependent FOXO3a cytoplasmic translocation is an important tumorigenic mechanism for escaping from apoptosis in cancer cells. In the present study, we examined whether non-phosphorylatable FOXO3a can inhibit cell growth of various follicular thyroid carcinoma (FTC) cell lines. Adenovirus carrying the FOXO3a-triple mutant (TM) sequence including point mutations at three Akt phosphorylation sites (Ad-FOXO3a-TM) was generated and transduced to the cells to mimic inhibition of Akt/FOXO3a signal. Transduction of Ad-FOXO3a-TM to FTC133 cells induced cell cycle arrest and apoptosis. Injection of Ad-FOXO3a-TM suppressed the growth of xenograft tumors in athymic mice. Consequently, our results indicate that gene therapy based on Ad-FOXO3a-TM has therapeutic potential for FTC. © 2011 Elsevier Ireland Ltd.